A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

NCT ID: NCT02670083

Last Updated: 2020-07-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

813 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-22

Study Completion Date

2019-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (Q4W) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose. Participants will then have the option to enter the Open Label Extension (OLE) study if eligible. Participants who do not enter the OLE study will have additional follow-up visits at 16 and 52 weeks after the last dose, primarily for safety and also for limited efficacy assessments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Crenezumab

Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.

Group Type EXPERIMENTAL

Crenezumab

Intervention Type DRUG

Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Crenezumab

Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Intervention Type DRUG

Placebo

Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Weight between 40 and 120 kilograms (Kg) inclusive
* Availability of a person (referred to as the "caregiver") who in the investigator's judgment:
* Has frequent and sufficient contact with the participant to be able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits (which require partner input for scale completion), signs the necessary consent form, and has sufficient cognitive capacity to accurately report upon the participant's behavior and cognitive and functional abilities
* Fluency in the language of the tests used at the study site
* Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)
* Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys beta-amyloid(1-42) test system or amyloid PET scan by qualitative read by the core/central PET laboratory
* Demonstrated abnormal memory function at screening (up to 4 weeks before screening begins) or screening (FCSRT cueing index =\<0.67 AND free recall =\<27)
* Screening mini mental state examination (MMSE) score of greater than or equal to (\>=) 22 points and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 or 1.0
* Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment (MCI)
* If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening
* Participant must have completed at least 6 years of formal education after the age of 5 years

Exclusion Criteria

* Any evidence of a condition other than AD that may affect cognition such as other dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological sequelae.
* History of major psychiatric illness such as schizophrenia or major depression (if not considered in remission)
* At risk of suicide in the opinion of the investigator
* Any abnormal MRI findings, such as presence of cerebral vascular pathology, cortical stroke, etc or inability to tolerate MRI procedures or contraindication to MRI
* Unstable or clinically significant cardiovascular (e.g., myocardial infarction), kidney or liver disease
* Uncontrolled hypertension
* Screening hemoglobin A1c (HbA1C) \>8%
* Poor peripheral venous access
* History of cancer except:

If considered to be cured or If not being actively treated with anti-cancer therapy or radiotherapy

\- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner Alzheimer's Institute

Phoenix, Arizona, United States

Site Status

Pharmacology Research Inst

Encino, California, United States

Site Status

Collaborative Neuroscience Network Inc.

Long Beach, California, United States

Site Status

Alliance for Wellness, dba Alliance for Research

Long Beach, California, United States

Site Status

Pharmacology Research Institute

Los Alamitos, California, United States

Site Status

USC Keck School Of Medicine

Los Angeles, California, United States

Site Status

UCLA Medical Center, Department of Neurology

Los Angeles, California, United States

Site Status

Pharmacology Research Inst

Newport Beach, California, United States

Site Status

Shankle Clinic

Newport Beach, California, United States

Site Status

Stanford Univ Medical Center

Palo Alto, California, United States

Site Status

Anderson Clinical Research, Inc.

Redlands, California, United States

Site Status

University of California, Davis; Alzheimers Disease Center, Department of Neurology

Sacramento, California, United States

Site Status

UCSF - Memory and Aging Center

San Francisco, California, United States

Site Status

Neurological Research Inst

Santa Monica, California, United States

Site Status

North Bay Neuro Science Institute

Sebastopol, California, United States

Site Status

Associated Neurologists PC - Danbury

Danbury, Connecticut, United States

Site Status

Institute for Neurodegenerative Disorders

New Haven, Connecticut, United States

Site Status

Yale University School Of Medicine

New Haven, Connecticut, United States

Site Status

Research Center for Clinical Studies, Inc.

Norwalk, Connecticut, United States

Site Status

Bradenton Research Center

Bradenton, Florida, United States

Site Status

Quantum Laboratories

Deerfield Beach, Florida, United States

Site Status

Brain Matters Research, Inc.

Delray Beach, Florida, United States

Site Status

Galiz Research, LLC

Hialeah, Florida, United States

Site Status

Jacksonville Center For Clinical Research

Jacksonville, Florida, United States

Site Status

Alzheimer's Research and Treatment Center

Lake Worth, Florida, United States

Site Status

Merritt - Island Medical Research

Merritt Island, Florida, United States

Site Status

Miami Jewish Health Systems

Miami, Florida, United States

Site Status

Renstar Medical Research

Ocala, Florida, United States

Site Status

Bioclinica Research

Orlando, Florida, United States

Site Status

Progressive Medical Research

Port Orange, Florida, United States

Site Status

Johnnie B. Byrd Sr. Alzheimer's Center & Research Institute

Tampa, Florida, United States

Site Status

Stedman Clinical Trials, LLC

Tampa, Florida, United States

Site Status

Compass Research

The Villages, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

NeuroStudies.net, LLC

Decatur, Georgia, United States

Site Status

Alexian Brothers Neurosci Inst

Elk Grove Village, Illinois, United States

Site Status

Southern Illinois University, School of Medicine

Springfield, Illinois, United States

Site Status

Indiana University

Indianapolis, Indiana, United States

Site Status

MidAmerica Neuroscience Institute

Prairie Village, Kansas, United States

Site Status

Maine Research Associates

Auburn, Maine, United States

Site Status

MMP Neurology

Scarborough, Maine, United States

Site Status

Springfield Neurology Associates

Springfield, Massachusetts, United States

Site Status

Precise Research Centers

Flowood, Mississippi, United States

Site Status

The Cognitive and Research Center of New Jersey

Springfield, New Jersey, United States

Site Status

Advanced Memory Research Institute of NJ

Toms River, New Jersey, United States

Site Status

Albany Medical Faculty Physicians COmmunity Division. The Neurology Group

Albany, New York, United States

Site Status

Neurological Associates of Albany, PC

Albany, New York, United States

Site Status

Dent Neurological Institute

Amherst, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

South Shore Neurologic Associates P.C.

Patchogue, New York, United States

Site Status

Behavioral Health Research

Charlotte, North Carolina, United States

Site Status

Guilford Neurologic Associates

Greensboro, North Carolina, United States

Site Status

Valley Medical Primary Care

Centerville, Ohio, United States

Site Status

Insight Clinical Trials LLC

Shaker Heights, Ohio, United States

Site Status

Oklahoma Clinical Research

Oklahoma City, Oklahoma, United States

Site Status

Cutting Edge Research Group

Oklahoma City, Oklahoma, United States

Site Status

Central States Research

Tulsa, Oklahoma, United States

Site Status

Summit Research Network Inc.

Portland, Oregon, United States

Site Status

Drexel Univ College of Med; Clinical Research Group

Philadelphia, Pennsylvania, United States

Site Status

Abington Neurological Associates

Willow Grove, Pennsylvania, United States

Site Status

Senior Adults Specialty Research

Austin, Texas, United States

Site Status

Kerwin Research Center, LLC

Dallas, Texas, United States

Site Status

University of North Texas Health Science Center; Fort Worth Patient Care Center

Fort Worth, Texas, United States

Site Status

Sentara Medical Group

Norfolk, Virginia, United States

Site Status

National Clinical Research Inc.-Richmond

Richmond, Virginia, United States

Site Status

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

The Queen Elizabeth Hospital; Neurology

Woodville, South Australia, Australia

Site Status

Caulfield Hospital; Aged Psychiatry Research Unit

Caulfield, Victoria, Australia

Site Status

Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre

Heidelberg West, Victoria, Australia

Site Status

Neurodegenerative Disorders Research; Neurology

West Perth, Western Australia, Australia

Site Status

Konventhospital Barmherzige Brüder; Neurologie I

Linz, , Austria

Site Status

UZ Gent

Ghent, , Belgium

Site Status

ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD; Clinic of Neurology and Sleep Medicine

Sofia, , Bulgaria

Site Status

Alexandrovska hospital; Neurology Department

Sofia, , Bulgaria

Site Status

Vancouver Hospital - UBC Hospital Site

Vancouver, British Columbia, Canada

Site Status

Vancouver Island Health Authority

Victoria, British Columbia, Canada

Site Status

Parkwood Hospital; Geriatric Medicine

London, Ontario, Canada

Site Status

Bruyere Continuing Care

Ottawa, Ontario, Canada

Site Status

Kawartha Centre - Redefining Healthy Aging

Peterborough, Ontario, Canada

Site Status

The Centre for Memory and Aging

Toronto, Ontario, Canada

Site Status

Toronto Western Hospital

Toronto, Ontario, Canada

Site Status

Devonshire Clinical Research Inc.

Woodstock, Ontario, Canada

Site Status

CHA Hopital de I enfant-Jesus

Québec, Quebec, Canada

Site Status

Hospital Clínica Biblica

San José, , Costa Rica

Site Status

ICIMED Instituto de Investigación en Ciencias Médicas

San José, , Costa Rica

Site Status

Clinical Hospital Centre Zagreb;Clinic for Neurology

Zagreb, , Croatia

Site Status

Charles University, Medical faculty, Hradec Kralove ;Department of Neurology

Hradec Králové, , Czechia

Site Status

General Teaching Hospital, Departmetn of Neurology

Prague, , Czechia

Site Status

Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken

Aarhus N, , Denmark

Site Status

Rigshospitalet, Hukommelsesklinikken

København Ø, , Denmark

Site Status

Terveystalo Tampere

Tampere, , Finland

Site Status

CRST Oy

Turku, , Finland

Site Status

Hopital Avicenne; Neurologie

Bobigny, , France

Site Status

Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie

Bron, , France

Site Status

Hopital Gui de Chauliac; Neurologie

Montpellier, , France

Site Status

Hopital Lariboisiere

Paris, , France

Site Status

CHU Poitiers - Hopital La Miletrie

Poitiers, , France

Site Status

Hopital Hautepierre; Centre dInvestigation Clinique

Strasbourg, , France

Site Status

CHU Toulouse - La Grave

Toulouse, , France

Site Status

Neurologische Praxis Dr. Andrej Pauls

München, , Germany

Site Status

Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie

München, , Germany

Site Status

Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie

Münster, , Germany

Site Status

Steinwachs Klaus; Arztpraxis fur Neurologie u. Psychiatrie

Nuremberg, , Germany

Site Status

Universitätsklinikum Rostock Zentrum für Nervenheilkunde

Rostock, , Germany

Site Status

Universitätsklinikum Ulm; Klinik für Neurologie

Ulm, , Germany

Site Status

Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz

Westerstede, , Germany

Site Status

Forschungszentrum Ruhr

Witten, , Germany

Site Status

Prince of Wales Hospital; Dept. of Medicine & Therapeutics

Hong Kong, , Hong Kong

Site Status

Queen Mary Hospital, Division of Geriatric Medicine

Hong Kong, , Hong Kong

Site Status

Semmelweis University; Department of Neurology

Budapest, , Hungary

Site Status

Szabolcs-Szatmár-Bereg Megyei Kórházak - Jósa András Oktatókórház; Pszichiátria

Nyíregyháza, , Hungary

Site Status

University of Szeged; Department of Psychiatry

Szeged, , Hungary

Site Status

Szent Borbala Korhaz; Neurologiai es Stroke Osztaly

Tatabánya, , Hungary

Site Status

Jávorszky Ödön Kórház, Neurológia és stroke osztály

Vác, , Hungary

Site Status

Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica

Rome, Lazio, Italy

Site Status

Ospedale San Giovanni Calibita Fatebenefratell;Neurologia

Rome, Lazio, Italy

Site Status

Ente Ospedaliero Ospedali Galliera; Ambulatorio di Neurologia

Genoa, Liguria, Italy

Site Status

Casa di Cura Policlinico; Dipartimento di Scienze Neuroriabilitative

Milan, Lombardy, Italy

Site Status

Ospedale S. Maria Nascente; Fondazione Don Gnocchi; Dip. Neurologia Riabilitativa

Milan, Lombardy, Italy

Site Status

Ospedale Casati Passirana di Rho; Centro Regionale Alzheimer

Passirana, Lombardy, Italy

Site Status

Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; S.C. Geriatria

Perugia, Umbria, Italy

Site Status

Miyoshi Clinic of Neurology, Hananosato

Hiroshima, , Japan

Site Status

National Hospital Organization Hiroshima-Nishi Medical Center

Hiroshima, , Japan

Site Status

Rakuwakai Otowarehabilitation Hospital

Kyoto, , Japan

Site Status

Mie University Hospital

Mie, , Japan

Site Status

National Hospital Organization Matsumoto Medical Center

Nagano, , Japan

Site Status

Saigata Medical Center

Niigata, , Japan

Site Status

Katayama Medical Clinic

Okayama, , Japan

Site Status

Tokyo Medical University Hospital

Tokyo, , Japan

Site Status

Tokyo Metropolitan Geriatric Hospital

Tokyo, , Japan

Site Status

National Center of Neurology and Psychiatry

Tokyo, , Japan

Site Status

Vilnius University Hospital Santariskiu Clinic

Vilnius, , Lithuania

Site Status

Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC

Culiacán, , Mexico

Site Status

Hospital Uni; Dr. Jose E. Gonzalez

Monterrey, , Mexico

Site Status

AVIX Investigación Clínica S.C

Monterrey, , Mexico

Site Status

Hospital Universitario de Saltillo

Saltillo, , Mexico

Site Status

Podlaskie Centrum Psychogeriatrii

Bialystok, , Poland

Site Status

NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek

Poznan, , Poland

Site Status

NEURO-CARE Sp. z o.o. Sp. Komandytowa

Siemianowice Śląskie, , Poland

Site Status

Przychodnia Specjalistyczna PROSEN

Warsaw, , Poland

Site Status

Centrum Medyczne NeuroProtect

Warsaw, , Poland

Site Status

Optimum

Warsaw, , Poland

Site Status

Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia

Amadora, , Portugal

Site Status

Hospital Beatriz Angelo; Servico de Neurologia

Loures, , Portugal

Site Status

State Autonomous Healthcare Institution "Republican Clinical Neurological Center

Kazan', , Russia

Site Status

State autonomous institution of healthcare Inter-regional clinical and diagnostic center

Kazan', , Russia

Site Status

Institution of RAMS (Mental Health Research Center of RAMS)

Moscow, , Russia

Site Status

SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF

Moscow, , Russia

Site Status

SHI City Psychoneurological Dispensary #7

Saint Petersburg, , Russia

Site Status

Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department

Saint Petersburg, , Russia

Site Status

City Clinical Hospital # 2 n.a. V.I. Razumovsky

Saratov, , Russia

Site Status

University Medical Centre Maribor

Maribor, , Slovenia

Site Status

Chonnam National University Hospital

Gwangju, , South Korea

Site Status

Inha University Hospital

Incheon, , South Korea

Site Status

Konkuk University Medical Center

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

KyungHee Medical Center

Seoul, , South Korea

Site Status

Ewha Womans University Mokdong Hospital; Dept of Neurology

Seoul, , South Korea

Site Status

Fundació ACE

BArcelon, Barcelona, Spain

Site Status

Hospital Universitari de Bellvitge; Servicio de Neurologia

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Hospital Sant Joan de Deu; Servicio de Neurología

Manresa, Barcelona, Spain

Site Status

Hospital General De Catalunya; Servicio de Neurologia

Sant Cugat del Vallès, Barcelona, Spain

Site Status

Hospital Mutua De Terrasa; Servicio de Neurologia

Terrassa, Barcelona, Spain

Site Status

Hospital Virgen del Puerto. Servicio de Neurología

Plasencia, Caceres, Spain

Site Status

Hospital Universitario Marques de Valdecilla; Servicio de Neurología

Santander, Cantabria, Spain

Site Status

Clinica Universitaria de Navarra; Servicio de Neurología

Pamplona, Navarre, Spain

Site Status

Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría

Salamaca, Salamanca, Spain

Site Status

Hospital General Universitario de Albacete; Servicio de Neurología

Albacete, , Spain

Site Status

Hospital Vall d'Hebron; Servicio de Neurología

Barcelona, , Spain

Site Status

Hospital Universitario de Burgos. Servicio de Neurología

Burgos, , Spain

Site Status

Clinica Ruber, 4 planta; Servicio de Neurologia

Madrid, , Spain

Site Status

Universitario de La Princesa; Servicio de Neurología

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre; Servicio de Neurologia

Madrid, , Spain

Site Status

Hospital Regional Universitario Carlos Haya; Servicio de Neurologia

Málaga, , Spain

Site Status

Hospital Universitario Virgen de Arrixaca; Servicio de Neurología

Murcia, , Spain

Site Status

Hospital Universitario la Fe; Servicio de Neurologia

Valencia, , Spain

Site Status

Servicio de Neurología Hospital Viamed Montecanal.

Zaragoza, , Spain

Site Status

Skånes Universitetssjukhus Malmö, Minneskliniken

Malmo, , Sweden

Site Status

Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry

Mölndal, , Sweden

Site Status

Karolinska Uni Hospital, Huddinge; Dept. of Geriatric Med

Stockholm, , Sweden

Site Status

Universitäres Zentrum für Altersmedizin und Rehabilitation

Basel, , Switzerland

Site Status

Hacettepe University School of Medicine; Neurology

Ankara, , Turkey (Türkiye)

Site Status

Osmangazi University School of Medicine,Neurology Department

Eskişehir, , Turkey (Türkiye)

Site Status

Istanbul University Istanbul School of Medicine; Neurology

Istanbul, , Turkey (Türkiye)

Site Status

Ondokuz Mayis University School of Medicine; Neurology

Samsun, , Turkey (Türkiye)

Site Status

Regional mental hospital; Department of psychiatry, psychology and sexology

Lviv, KIEV Governorate, Ukraine

Site Status

National Medical Academy of Postgraduate Education named after P.L.Shupik; Neurology Department #1

Kiev, , Ukraine

Site Status

D.F.Chebotarev Institute of Gerontology NAMS;Depart of Age Physiology&Pathology of Nervous System

Kiev, , Ukraine

Site Status

Royal Preston Hospital

Blackburn, , United Kingdom

Site Status

Surrey and Borders NHS Foundation Trust; Brain Science Research Unit

Chertsey, , United Kingdom

Site Status

Coventry and Warwickshire Partnership NHS Trust

Coventry, , United Kingdom

Site Status

St George's Hospital

London, , United Kingdom

Site Status

Charing Cross Hospital

London, , United Kingdom

Site Status

Manchester Royal Infirmary

Manchester, , United Kingdom

Site Status

Campus for Ageing and Vitality

Newcastle upon Tyne, , United Kingdom

Site Status

John Radcliffe Hospital

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Bulgaria Canada Costa Rica Croatia Czechia Denmark Finland France Germany Hong Kong Hungary Italy Japan Lithuania Mexico Poland Portugal Russia Slovenia South Korea Spain Sweden Switzerland Turkey (Türkiye) Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Chandler JM, Lansdall CJ, Ye W, McDougall F, Belger M, Toth B, Mi X, Sink KM, Atkins AS. The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity. J Prev Alzheimers Dis. 2025 Sep;12(8):100261. doi: 10.1016/j.tjpad.2025.100261. Epub 2025 Jul 1.

Reference Type DERIVED
PMID: 40603145 (View on PubMed)

Teng E, Manser PT, Shah M, Pickthorn K, Hu N, Djakovic S, Swendsen H, Blendstrup M, Faccin G, Ostrowitzki S, Sink KM. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). J Prev Alzheimers Dis. 2023;10(1):41-49. doi: 10.14283/jpad.2022.101.

Reference Type DERIVED
PMID: 36641609 (View on PubMed)

Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH, Grimmer T, Selkoe DJ, Schneider A, Blondeau K, Hu N, Quartino A, Clayton D, Dolton M, Dang Y, Ostaszewski B, Sanabria-Bohorquez SM, Rabbia M, Toth B, Eichenlaub U, Smith J, Honigberg LA, Doody RS. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022 Nov 1;79(11):1113-1121. doi: 10.1001/jamaneurol.2022.2909.

Reference Type DERIVED
PMID: 36121669 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-003034-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BN29552

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.